{"id":"sofosbuvir-ribavirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1259059","moleculeType":"Small molecule","molecularWeight":"529.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide prodrug that, when activated intracellularly, acts as a chain terminator of HCV RNA synthesis by inhibiting the NS5B polymerase. Ribavirin is a broad-spectrum antiviral nucleoside analog that increases mutation rates in the viral genome and enhances immune responses. Together, this combination directly targets viral replication and has been used historically for HCV treatment, though it has largely been superseded by direct-acting antiviral combinations.","oneSentence":"Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, while ribavirin is a nucleoside analog that enhances viral suppression through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:36.813Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT06180590","phase":"","title":"The Efficacy of Vosevi in Treating DAA-experienced Patients","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2023-02-28","conditions":"Chronic Hepatitis C, Medication Reaction","enrollment":200},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT03702218","phase":"EARLY_PHASE1","title":"Hepatitis C Positive Donor Into Hepatitis C Negative Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT04653818","phase":"PHASE4","title":"HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-10-05","conditions":"Hepatocellular Carcinoma, Hepatitis C, Neoplasm Recurrence","enrollment":84},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT03042520","phase":"","title":"Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-08","conditions":"Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia","enrollment":200},{"nctId":"NCT02455167","phase":"PHASE3","title":"Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-05","conditions":"Hepatitis C","enrollment":9},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT02966795","phase":"PHASE3","title":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-01-25","conditions":"Hepatitis C Virus (HCV)","enrollment":84},{"nctId":"NCT02723084","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-08","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":136},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02292719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-19","conditions":"Chronic Hepatitis C Virus Infection","enrollment":70},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT04729153","phase":"","title":"Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02","conditions":"Covid19","enrollment":100},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT04662138","phase":"","title":"Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-08-24","conditions":"Hepatitis C, Relapse, Antivirals","enrollment":100},{"nctId":"NCT03283176","phase":"","title":"Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals","enrollment":50},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT04391985","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":113},{"nctId":"NCT04387526","phase":"PHASE2, PHASE3","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2016-04-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":946},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT04385407","phase":"PHASE2","title":"Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-04","conditions":"Chronic Hepatitis C Virus Infection","enrollment":203},{"nctId":"NCT04382339","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-03","conditions":"Hepatitis C Virus Infection","enrollment":99},{"nctId":"NCT02468648","phase":"PHASE2","title":"Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2015-06-09","conditions":"Chronic Hepatitis C","enrollment":72},{"nctId":"NCT02994056","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-23","conditions":"Hepatitis C Virus Infection","enrollment":32},{"nctId":"NCT02249182","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-11-05","conditions":"Hepatitis C Virus Infection","enrollment":226},{"nctId":"NCT03092375","phase":"PHASE3","title":"Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-04-20","conditions":"Hepatitis C, HCV","enrollment":177},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT04038320","phase":"","title":"Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine","status":"COMPLETED","sponsor":"Right to Care","startDate":"2018-03-26","conditions":"Hepatitis C Virus","enrollment":868},{"nctId":"NCT03579576","phase":"","title":"Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar","status":"COMPLETED","sponsor":"Right to Care","startDate":"2017-12-20","conditions":"Hepatitis C, Hepatitis B, HIV Infections","enrollment":803},{"nctId":"NCT03481036","phase":"NA","title":"DAA Therapy in Pediatric Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT02631772","phase":"PHASE4","title":"LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-06-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT02760355","phase":"NA","title":"Extrahepatic Insulin Resistance in Chronic Hepatitis C","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Insulin Resistance","enrollment":17},{"nctId":"NCT02175758","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07-07","conditions":"Hepatitis C Virus Infection","enrollment":106},{"nctId":"NCT02304159","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics","status":"COMPLETED","sponsor":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","startDate":"2015-01","conditions":"Hepatitis C, Cirrhosis","enrollment":39},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03069365","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-28","conditions":"Hepatitis C Virus (HCV)","enrollment":101},{"nctId":"NCT02996682","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-26","conditions":"Hepatitis C Virus Infection","enrollment":102},{"nctId":"NCT02536313","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-29","conditions":"Hepatitis C Virus Infection","enrollment":49},{"nctId":"NCT02717949","phase":"PHASE4","title":"Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-02-25","conditions":"Liver Disease","enrollment":1},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT02781558","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-29","conditions":"Hepatitis C Virus Infection","enrollment":204},{"nctId":"NCT01987453","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"HCV Infection","enrollment":100},{"nctId":"NCT01984294","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"Chronic HCV Infection","enrollment":101},{"nctId":"NCT02010255","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-01","conditions":"Chronic HCV Infection","enrollment":334},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT02487030","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-09-07","conditions":"Hepatitis C Virus Infection","enrollment":255},{"nctId":"NCT02201953","phase":"PHASE3","title":"Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":558},{"nctId":"NCT02226549","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":47},{"nctId":"NCT02600351","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT01938430","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09","conditions":"Chronic HCV Infection","enrollment":339},{"nctId":"NCT01826981","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Chronic Hepatitis C","enrollment":359},{"nctId":"NCT01726517","phase":"PHASE2","title":"Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10","conditions":"Chronic Hepatitis C Virus","enrollment":100},{"nctId":"NCT01965535","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"HCV Infection","enrollment":155},{"nctId":"NCT02413593","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-04","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT01975675","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"Chronic HCV Infection","enrollment":341},{"nctId":"NCT02300103","phase":"PHASE2","title":"Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-01","conditions":"Hepatitis C Virus Infection","enrollment":69},{"nctId":"NCT01768286","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-01","conditions":"Chronic Hepatitis C Virus","enrollment":441},{"nctId":"NCT02472886","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-17","conditions":"Hepatitis C Virus Infection","enrollment":153},{"nctId":"NCT01701401","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-09","conditions":"Chronic Hepatitis C Virus","enrollment":870},{"nctId":"NCT02738333","phase":"PHASE3","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-12","conditions":"Hepatitis C Virus Infection","enrollment":239},{"nctId":"NCT01851330","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05","conditions":"Chronic Hepatitis C Virus","enrollment":647},{"nctId":"NCT01909804","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-06","conditions":"Hepatitis C","enrollment":323},{"nctId":"NCT02220998","phase":"PHASE3","title":"Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-09","conditions":"Hepatitis C Virus Infection","enrollment":269},{"nctId":"NCT02201901","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":268},{"nctId":"NCT02822794","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-25","conditions":"Hepatitis C Virus Infection","enrollment":117},{"nctId":"NCT01858766","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Hepatitis C","enrollment":379},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT02156570","phase":"PHASE4","title":"DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2014-10","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02804386","phase":"PHASE4","title":"Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon","status":"COMPLETED","sponsor":"PharmEvo Pvt Ltd","startDate":"2016-06","conditions":"Hepatitis C, Chronic","enrollment":573},{"nctId":"NCT03665766","phase":"","title":"Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-05-15","conditions":"Liver Transplantation","enrollment":126},{"nctId":"NCT02781649","phase":"PHASE4","title":"Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-07-20","conditions":"End-Stage Renal Disease, Hepatitis C","enrollment":10},{"nctId":"NCT01958281","phase":"PHASE2","title":"Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-07","conditions":"HCV Infection","enrollment":38},{"nctId":"NCT02214420","phase":"PHASE4","title":"SMV + SOF With/Without RBV for IFN-II Patients With CHC","status":"COMPLETED","sponsor":"SC Liver Research Consortium, LLC","startDate":"2014-10","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT03105349","phase":"PHASE4","title":"A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A","status":"WITHDRAWN","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-07-01","conditions":"HCV","enrollment":""},{"nctId":"NCT03343444","phase":"PHASE3","title":"Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents","status":"UNKNOWN","sponsor":"Egyptian Liver Hospital","startDate":"2017-04-15","conditions":"Hepatitis C Virus Infection, Response to Therapy of","enrollment":80},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT02673489","phase":"PHASE3","title":"A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-15","conditions":"Hepatitis C","enrollment":106},{"nctId":"NCT02605304","phase":"PHASE2","title":"12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2016-02-17","conditions":"HIV-1 Infection, Hepatitis C","enrollment":7}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"CEREBRAL INFARCTION"},{"count":1,"reaction":"GASTRIC ULCER HAEMORRHAGE"},{"count":1,"reaction":"HEPATIC FAILURE"},{"count":1,"reaction":"HEPATITIS C RNA INCREASED"},{"count":1,"reaction":"HEPATITIS CHOLESTATIC"}],"_approvalHistory":[],"publicationCount":190,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sofosbuvir-Ribavirin","genericName":"Sofosbuvir-Ribavirin","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, while ribavirin is a nucleoside analog that enhances viral suppression through multiple mechanisms. Used for Chronic hepatitis C virus (HCV) infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}